Dr Ross Chapman collaborated with a research team at the Netherlands Cancer Institute on a recent Nature paper which uncovered the crucial role a protein called Rev7 played in resistance to PARP inhibitors.
Crucial role for repair protein in cancer therapy
22 April 2015
A study involving researchers at the Wellcome Trust Centre for Human Genetics has uncovered why some tumours become resistant to an important class of anti-cancer drugs. Women with breast cancer caused by BRCA1 gene mutations can be treated with PARP inhibitors. but some tumours appear to become resistant to this treatment